HENRY SCHEIN® 2023 INVESTOR MEETING

Customers will rely on us for an exceptional experience, delivering differentiated solutions that make their practices more successful and improve patient outcomes.

Together, we make the world healthier.

Key Messages



Leading positions in the growing \$100bn¹ dental and alternate care medical products and services markets, and in the faster growing specialty and technology segments

2022–2024 BOLD+1 strategic plan provides a roadmap for **long-term sustainable high single/ low double-digit earnings growth**



Proven track record of innovation, product and service expansion, business development, and successful transformation

\mathcal{O}	
OF	ľ
MO	È
$\Box \sim$	١
	-

Deep and experienced executive team supported by a highly motivated Team Schein that is well-positioned to execute and deliver on the strategy and financial goals

2022–2024 Strategic Plan



Our **BOLD+1** Priorities Leading to Accelerating Growth

BUILD complementary software, specialty, and services to strategically shift our mix to high growth and high margin businesses

- Provide integrated solutions
- Accelerate both organic and inorganic growth of global specialty products and services
- Capitalize on unique data to develop
 additional proprietary solutions

OPERATIONALIZE One Distribution global footprint to:

- Deliver exceptional customer experience, increase efficiency, and sales growth
- Advance sales of our corporate brands
 portfolio

LEVERAGE One Schein to broaden and deepen relationships with our customers

DRIVE digital transformation for our customers and for Henry Schein

- Enhance personalized customer experience through our **global** e-commerce platform
- Advance connected open architecture clinical digital workflow solution
- +1 CREATE value for our stakeholders

1 Based on management estimates and excluding specialty drugs

HENRY SCHEIN® 2023 INVESTOR MEETING

A Suite of Differentiated Customer Solutions



Henry Schein's solutions enable:

- Improved patient experience
- Improved outcomes
- Increased case acceptance
- Increased practice efficiencies

#1 Global Distributor supported by

in Distrib



Uniquely positioned to provide solutions for general and specialist practitioners in alternate healthcare settings

Long-Term Financial Goals

	Long-Term Financial Goals
Total Sales Growth	6 – 8%
Non-GAAP Operating Margin Expansion	10bps+
Non-GAAP Diluted EPS Growth ¹	8 – 11%

1 Assumes interest rates, tax rates, depreciation, and foreign exchange are consistent with 2023 guidance

We have a long track record of strong financial performance

Financial Summary



- 2023 non-GAAP projected operating income growth in the high single-digit to low double-digit range (excluding PPE and COVID test kits)
- Long-term annual sales goal of 6–8% and non-GAAP diluted EPS goal of 8–11% growth
- Operating Income contribution from high-growth, high-margin Technology and Value-Added Services, and Specialty products expected to approach 40% of total in 2024